MedTrace Logo

Efficacy and Safety of Discontinuing 5-ASA in Patients With Inflammatory Bowel Disease

NCT06878495 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-05-29

No results posted yet for this study

Summary

This study aims to evaluate the long-term outcomes of discontinuing 5-ASA in UC and CD patients receiving stable biologic or immunomodulator therapy using a prospective cohort based in the Busan-Ulsan-Gyeongnam region. It seeks to determine whether discontinuing 5-ASA is a safe treatment strategy in modern IBD management.

Conditions

  • Ulcerative Colitis (UC)
  • Crohn's Disease
  • Inflammatory Bowel Disease (IBD)

Interventions

OTHER

Discontinuation of 5-ASA

Discontinuation of 5-ASA from the time of study enrollment.

Sponsors & Collaborators

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • Seung Min Hong, M.D. · Pusan National University Hospital

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-15
Primary Completion
2025-12-31
Completion
2025-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06878495 on ClinicalTrials.gov